Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

7
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
7
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

7
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
7
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

7
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
7
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

377
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
377
Overview of Metabolism01:40

Overview of Metabolism

25.5K
Living cells constantly carry out various chemical reactions which are necessary for their proper functioning. These reactions are interlinked to one another via multiple pathways. The collection of these chemical reactions is known as metabolism.
Plant Metabolism
Sunlight, the primary source of energy in plants, is first absorbed by the chlorophyll pigments present in their leaves. Plants then use this energy to carry out photosynthesis, where water is oxidized into oxygen and carbon dioxide...
25.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Astrocytic lipid dysregulation as an early driver of neurodegeneration.

Nature reviews. Neurology·2026
Same author

CRYAB is compromised in pathologically affected oligodendrocytes in multiple system atrophy.

Brain pathology (Zurich, Switzerland)·2026
Same author

Reduced serum interleukin-2 associates with higher motor severity and along with CD4 T cell alterations may be an early event in isolated REM Sleep Behaviour Disorder.

Brain, behavior, & immunity - health·2026
Same author

Ultra-rare variants in LAMA2 are risk factors for frontotemporal dementia and motor neuron disease.

Human molecular genetics·2026
Same author

Location and mapping of the human rostromedial tegmental nucleus and associated midbrain inhibitory nuclei regulating dopamine neurons.

Brain structure & function·2026
Same author

Systemic dysregulation of apolipoproteins in amyotrophic lateral sclerosis serum.

FEBS open bio·2026

Related Experiment Video

Updated: Apr 22, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.2K

Systemic metabolism in frontotemporal dementia.

Rebekah M Ahmed1, Mia MacMillan1, Lauren Bartley1

  • 1From Neuroscience Research Australia (R.M.A., M.M., L.B., G.M.H., M.C.K., J.R.H., O.P.), Sydney; Prince of Wales Clinical School (R.M.A., J.R.H.), School of Medical Sciences (G.M.H., O.P.), and ARC Centre of Excellence in Cognition and its Disorders (R.M.A., G.M.H., J.R.H., O.P.), the University of New South Wales, Sydney; and Sydney Medical School (M.C.K.), Brain and Mind Research Institute, University of Sydney, Australia.

Neurology
|October 12, 2014
PubMed
Summary

Frontotemporal dementia (FTD) patients show altered metabolism, including higher insulin and triglyceride levels and lower HDL cholesterol. These metabolic changes suggest peripheral insulin resistance in FTD.

More Related Videos

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level
07:28

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level

Published on: January 24, 2025

761
Metabolic Analysis of Drosophila melanogaster Larval and Adult Brains
07:06

Metabolic Analysis of Drosophila melanogaster Larval and Adult Brains

Published on: August 7, 2018

11.1K

Related Experiment Videos

Last Updated: Apr 22, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.2K
Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level
07:28

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level

Published on: January 24, 2025

761
Metabolic Analysis of Drosophila melanogaster Larval and Adult Brains
07:06

Metabolic Analysis of Drosophila melanogaster Larval and Adult Brains

Published on: August 7, 2018

11.1K

Area of Science:

  • Neuroscience
  • Metabolic Disorders
  • Dementia Research

Background:

  • Metabolic changes are implicated in neurodegenerative disease progression.
  • Motor neuron disease (MND) progression is thought to be influenced by metabolic factors.
  • Understanding metabolic alterations in frontotemporal dementia (FTD) is crucial for disease insight.

Purpose of the Study:

  • To document metabolic changes in FTD, specifically serum cholesterol and insulin levels.
  • To compare these metabolic changes with those in motor neuron disease.
  • To investigate the role of metabolism in FTD pathophysiology and progression.

Main Methods:

  • Analyzed fasting blood cholesterol, glucose, and insulin levels in 90 dementia patients (behavioral-variant FTD, semantic dementia, Alzheimer disease) and 19 controls.
  • Calculated insulin resistance using the homeostasis model assessment of insulin resistance (HOMA-IR).
  • Compared metabolic profiles between FTD subtypes, Alzheimer disease, and control groups.

Main Results:

  • Behavioral-variant FTD (bvFTD) patients exhibited lower HDL cholesterol and higher total cholesterol/HDL ratio and triglycerides versus controls.
  • Semantic dementia (SD) patients showed increased triglyceride levels compared to controls.
  • Both bvFTD and SD groups presented with elevated fasting insulin levels and HOMA-IR index compared to controls, with bvFTD showing higher levels than Alzheimer disease.

Conclusions:

  • Patients with bvFTD and SD demonstrate metabolic disturbances, including elevated triglycerides, insulin levels, and reduced HDL cholesterol, indicative of peripheral insulin resistance.
  • These metabolic factors may influence disease progression in FTD, similar to their proposed role in motor neuron disease.
  • Metabolic dysregulation is suggested as a potential contributor to the pathophysiology and progression of frontotemporal dementia.